49BA Stock Overview
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 49BA from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
BeiGene, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$218.00 |
| 52 Week High | US$228.00 |
| 52 Week Low | US$120.00 |
| Beta | 0.64 |
| 1 Month Change | 9.00% |
| 3 Month Change | 23.86% |
| 1 Year Change | 60.29% |
| 3 Year Change | 23.16% |
| 5 Year Change | 41.56% |
| Change since IPO | 806.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 49BA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.9% | -3.2% | 2.7% |
| 1Y | 60.3% | -7.9% | 17.0% |
Return vs Industry: 49BA exceeded the German Biotechs industry which returned -7.9% over the past year.
Return vs Market: 49BA exceeded the German Market which returned 17% over the past year.
Price Volatility
| 49BA volatility | |
|---|---|
| 49BA Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 49BA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 49BA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10,000 | John Oyler | www.beigene.com |
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company’s clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor.
BeiGene, Ltd. Fundamentals Summary
| 49BA fundamental statistics | |
|---|---|
| Market cap | €23.48b |
| Earnings (TTM) | -€787.37m |
| Revenue (TTM) | €3.09b |
7.6x
P/S Ratio-29.8x
P/E RatioIs 49BA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 49BA income statement (TTM) | |
|---|---|
| Revenue | CN¥23.51b |
| Cost of Revenue | CN¥3.84b |
| Gross Profit | CN¥19.67b |
| Other Expenses | CN¥25.66b |
| Earnings | -CN¥5.99b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | -56.16 |
| Gross Margin | 83.67% |
| Net Profit Margin | -25.50% |
| Debt/Equity Ratio | 29.6% |
How did 49BA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 11:15 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BeiGene, Ltd. is covered by 59 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Michael Meng | BOCI Research Ltd. |
| Yonglin Yan | BOCI Research Ltd. |